목적: In the present study, we investigated the therapeutic efficacy of cetuximab- based radioimmunotherapy of head and neck squamous cell carcinoma mouse model. 방법: EGFR expression on SNU1066 human head and neck squamous cell cancer (HNSCC) cells were determined by flow cytometry and immunostaining. Tumor delivery and biodistribution of cetuximab in tumor-bearing nude mice were evaluated with small animal PET using 64Cu-PCTA-cetuximab. The in vitro toxicity of cetuximab to HNSCC cells was evaluated by MTT assay. The tumor-bearing mice were then treated with normal saline, cetuximab and 177 Lu-PCTA- cetuximab and tumor growth was evaluated by caliper measurement. FDG PET was done after 177 Lu-PCTA-cetuximab radioimmunotherapy to evaluate tumor response. 결과:The good in vitro and in vivo quality control results suggested that 177 Lu-PCTA-cetuximab could be used as a radioimmunotherapy agent. The tumor uptake was 11.40 2.63, 17.94 5.26, and 16.83 2.63% ID/g for 177Lu-Cet at 24, 72, and 120 h. RIT with a single dose of 14.8 MBq of 177 Lu-PCTA-cetuximab significantly delayed tumor growth. 결론:The results showed that cetuximab can function as effective carriers for tumor-targeted delivery of radiation, and that RIT is promising for targeted therapy of EGFR-positive tumors, especially for those tumors that are resistant to antibody-based immunotherapy.